Kojima Y - Search Results

1

Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?

Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, Morizane C, Okusaka T. Hashimoto K, et al. Among authors: kojima y. Oncology. 2009;77(3-4):217-23. doi: 10.1159/000236022. Epub 2009 Sep 4. Oncology. 2009. PMID: 19729980

2

Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis.

Ikeda M, Okusaka T, Ueno H, Morizane C, Iwasa S, Hagihara A, Kojima Y. Ikeda M, et al. Among authors: kojima y. Oncology. 2007;72(3-4):188-93. doi: 10.1159/000112805. Epub 2007 Dec 20. Oncology. 2007. PMID: 18097170

3

Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.

Ikeda M, Okusaka T, Ueno H, Morizane C, Kojima Y, Iwasa S, Hagihara A. Ikeda M, et al. Among authors: kojima y. Jpn J Clin Oncol. 2008 Oct;38(10):675-82. doi: 10.1093/jjco/hyn087. Epub 2008 Aug 20. Jpn J Clin Oncol. 2008. PMID: 18716041

4

Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.

Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Hagihara A, Iwasa S, Kojima Y. Tanaka T, et al. Among authors: kojima y. Jpn J Clin Oncol. 2008 Nov;38(11):755-61. doi: 10.1093/jjco/hyn098. Epub 2008 Oct 8. Jpn J Clin Oncol. 2008. PMID: 18845521

5

Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.

Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N. Iwasa S, et al. Among authors: kojima y. Jpn J Clin Oncol. 2010 Apr;40(4):313-8. doi: 10.1093/jjco/hyp173. Epub 2010 Jan 4. Jpn J Clin Oncol. 2010. PMID: 20047862

6

Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.

Soeda A, Morita-Hoshi Y, Kaida M, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Heike Y. Soeda A, et al. Among authors: kojima y. Jpn J Clin Oncol. 2010 Dec;40(12):1184-8. doi: 10.1093/jjco/hyq112. Epub 2010 Jul 22. Jpn J Clin Oncol. 2010. PMID: 20656693

7

Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.

Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A. Suzuki E, et al. Among authors: kojima y. Oncology. 2010;79(1-2):39-45. doi: 10.1159/000318020. Epub 2010 Nov 10. Oncology. 2010. PMID: 21063134

8

Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.

Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Takaue Y, Heike Y. Kaida M, et al. Among authors: kojima y. J Immunother. 2011 Jan;34(1):92-9. doi: 10.1097/CJI.0b013e3181fb65b9. J Immunother. 2011. PMID: 21150717 Clinical Trial.

9

Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.

Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T. Morizane C, et al. Among authors: kojima y. Cancer Chemother Pharmacol. 2012 Apr;69(4):957-64. doi: 10.1007/s00280-011-1786-6. Epub 2011 Nov 26. Cancer Chemother Pharmacol. 2012. PMID: 22120961 Clinical Trial.

10

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.

Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Morizane C, et al. Among authors: kojima y. Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402. Ann Oncol. 2019. PMID: 31566666 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,264 results

Search Page

Filters